Overview

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
A mass balance study to determine the routes and rates of elimination of radioactivity, to determine total radioactivity in plasma and whole blood over time and compare levels to JTZ-951 and drug-derived entities in plasma and to determine pharmacokinetic (PK) parameters of JTZ-951 and its metabolite(s).
Phase:
Phase 1
Details
Lead Sponsor:
Akros Pharma Inc.